van Moorselaar RJA - Search Results

1

The oncological characteristics of non-prostate-specific membrane antigen (PSMA)-expressing primary prostate cancer on preoperative PSMA positron emission tomography/computed tomography.

Veerman H, Donswijk M, Bekers E, Bodar YJL, Meijer D, van Moorselaar RJA, Oprea-Lager DE, van der Noort V, van Leeuwen PJ, Vis AN, van der Poel HG. Veerman H, et al. Among authors: van leeuwen pj, van moorselaar rja, van der poel hg, van der noort v. BJU Int. 2022 Dec;130(6):750-753. doi: 10.1111/bju.15896. Epub 2022 Sep 30. BJU Int. 2022. PMID: 36117468 Free PMC article. No abstract available.

2

Intraprostatic testosterone and dihydrotestosterone. Part I: concentrations and methods of determination in men with benign prostatic hyperplasia and prostate cancer.

van der Sluis TM, Vis AN, van Moorselaar RJ, Bui HN, Blankenstein MA, Meuleman EJ, Heijboer AC. van der Sluis TM, et al. BJU Int. 2012 Jan;109(2):176-82. doi: 10.1111/j.1464-410X.2011.10651.x. Epub 2011 Oct 12. BJU Int. 2012. PMID: 21992222 Review.

3

Intraprostatic testosterone and dihydrotestosterone. Part II: concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancer.

van der Sluis TM, Meuleman EJ, van Moorselaar RJ, Bui HN, Blankenstein MA, Heijboer AC, Vis AN. van der Sluis TM, et al. BJU Int. 2012 Jan;109(2):183-8. doi: 10.1111/j.1464-410X.2011.10652.x. Epub 2011 Oct 12. BJU Int. 2012. PMID: 21992404 Review.

4

Lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry.

van der Sluis TM, Bui HN, Meuleman EJ, Heijboer AC, Hartman JF, van Adrichem N, Boevé E, de Ronde W, van Moorselaar RJ, Vis AN. van der Sluis TM, et al. J Urol. 2012 May;187(5):1601-6. doi: 10.1016/j.juro.2011.12.063. Epub 2012 Mar 14. J Urol. 2012. PMID: 22425112

5

Serum testosterone plays an important role in the metastatic ability of castration resistant prostate cancer.

van der Sluis TM, Bijnsdorp IV, Jacobs JJ, Meuleman EJ, Rozendaal L, Geldof AA, van Moorselaar RJ, Vis AN. van der Sluis TM, et al. World J Urol. 2013 Apr;31(2):261-6. doi: 10.1007/s00345-012-0972-4. Epub 2012 Oct 19. World J Urol. 2013. PMID: 23080125

6

Relationship between body mass index and serum testosterone concentration in patients receiving luteinizing hormone-releasing hormone agonist therapy for prostate cancer.

van der Sluis TM, van Moorselaar RJ, Meuleman EJ, ter Haar RW, Bui HN, Heijboer AC, Vis AN. van der Sluis TM, et al. Urology. 2013 May;81(5):1005-9. doi: 10.1016/j.urology.2013.01.014. Epub 2013 Mar 7. Urology. 2013. PMID: 23465153

7

Risk of disease flare with LHRH agonist therapy in men with prostate cancer: myth or fact?

Vis AN, van der Sluis TM, Al-Itejawi HHM, van Moorselaar RJA, Meuleman EJH. Vis AN, et al. Among authors: van der sluis tm, van moorselaar rja. Urol Oncol. 2015 Jan;33(1):7-15. doi: 10.1016/j.urolonc.2014.04.016. Epub 2014 Aug 20. Urol Oncol. 2015. PMID: 25159013 Review.

8

Development of a patient decision aid for the treatment of localised prostate cancer: a participatory design approach.

Al-Itejawi HH, van Uden-Kraan CF, Vis AN, Nieuwenhuijzen JA, Hofstee MJ, van Moorselaar RJ, Verdonck-de Leeuw IM. Al-Itejawi HH, et al. J Clin Nurs. 2016 Apr;25(7-8):1131-44. doi: 10.1111/jocn.13120. Epub 2016 Feb 16. J Clin Nurs. 2016. PMID: 26880526

9

First-line non-cytotoxic therapy in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: a systematic review of 10 randomised clinical trials.

Poorthuis MHF, Vernooij RWM, van Moorselaar RJA, de Reijke TM. Poorthuis MHF, et al. Among authors: van moorselaar rja. BJU Int. 2017 Jun;119(6):831-845. doi: 10.1111/bju.13764. Epub 2017 Feb 28. BJU Int. 2017. PMID: 28063195 Review.

10

Benefits of Using Stereotactic Body Radiotherapy in Patients With Metachronous Oligometastases of Hormone-Sensitive Prostate Cancer Detected by [18F]fluoromethylcholine PET/CT.

Bouman-Wammes EW, van Dodewaard-De Jong JM, Dahele M, Cysouw MCF, Hoekstra OS, van Moorselaar RJA, Piet MAH, Verberne HJ, Bins AD, Verheul HMW, Slotman BJ, Oprea-Lager DE, Van den Eertwegh AJM. Bouman-Wammes EW, et al. Among authors: van den eertwegh ajm, van dodewaard de jong jm, van moorselaar rja. Clin Genitourin Cancer. 2017 Oct;15(5):e773-e782. doi: 10.1016/j.clgc.2017.03.009. Epub 2017 Mar 29. Clin Genitourin Cancer. 2017. PMID: 28462855

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

191 results

Search Page

Filters